{"organizations": [], "uuid": "5dde64344e7555c160ca9075be997cbb8eda4c6c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-prometic-presents-new-pbi-4050-cli/brief-prometic-presents-new-pbi-4050-clinical-data-from-ongoing-alstrm-syndrome-phase-2-trial-idUSFWN1RP0GE", "country": "US", "domain_rank": 408, "title": "BRIEF-Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-12T13:38:00.000+03:00", "replies_count": 0, "uuid": "5dde64344e7555c160ca9075be997cbb8eda4c6c"}, "author": "", "url": "https://www.reuters.com/article/brief-prometic-presents-new-pbi-4050-cli/brief-prometic-presents-new-pbi-4050-clinical-data-from-ongoing-alstrm-syndrome-phase-2-trial-idUSFWN1RP0GE", "ord_in_thread": 0, "title": "BRIEF-Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial", "locations": [], "entities": {"persons": [{"name": "dat", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "prometic life sciences inc", "sentiment": "none"}, {"name": "trial reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12, 2018 / 10:39 AM / Updated 22 minutes ago BRIEF-Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial Reuters Staff \nApril 12 (Reuters) - Prometic Life Sciences Inc: \n* PROMETIC PRESENTS NEW PBI-4050 CLINICAL DATA FROM ONGOING ALSTRöM SYNDROME PHASE 2 TRIAL \n* PBI-4050 DECREASED INSULIN RESISTANCE IN LIVER \n* FAT BIOPSIES FURTHER DEMONSTRATE PBI-4050 CLINICAL ACTIVITY \n* CLINICAL ACTIVITY AND TOLERABILITY OF PBI-4050 WERE SUSTAINED WITH PROLONGED TREATMENT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-12T13:38:00.000+03:00", "crawled": "2018-04-12T14:16:37.020+03:00", "highlightTitle": ""}